Opus Genetics Highlights Significant Progress in 2025 and Upcoming Catalysts in 2026
Opus Genetics highlighted its progress achieved during 2025 and upcoming catalysts in 2026. OPGx-BEST1: First participant dosed in Phase 1/2 trial with enrollment ongoing. Initial data expected this quarter at Macula Society with 3-month results from the entire Cohort 1 expected in mid-2026. OPGx-BEST1 is potentially eligible for multiple regulatory designations which the Company expects to file for in 2026. OPGx-LCA5: Enrollment ongoing in run-in period for planned, adaptive pivotal Phase 3 trial. Dosing with OPGx-LCA5 in the Phase 3 trial expected in the second half of 2026. Pre-Clinical Gene Therapy Pipeline: Multiple partnerships with patient advocacy organizations are increasing awareness in the IRD community and providing non-dilutive funding for pre-clinical testing of Opus Genetics gene therapy pipeline. Phentolamine Ophthalmic Solution 0.75%: Supplemental New Drug Application submitted for the treatment of presbyopia, with an anticipated regulatory decision by the end of 2026. LYNX-3, the second pivotal Phase 3 trial in keratorefractive participants with visual disturbances under mesopic, low-contrast conditions, is ongoing with topline results expected in the first half of 2026.
